Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Free Report) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 295,000 shares, a growth of 116.8% from the June 30th total of 136,100 shares. Currently, 10.9% of the company’s shares are sold short. Based on an average trading volume of 488,800 shares, the short-interest ratio is currently 0.6 days.
Seelos Therapeutics Stock Down 6.6 %
NASDAQ:SEEL traded down $0.03 during midday trading on Friday, hitting $0.44. The stock had a trading volume of 298,842 shares, compared to its average volume of 1,329,906. The stock has a 50-day moving average of $0.85 and a 200 day moving average of $4.14. Seelos Therapeutics has a one year low of $0.43 and a one year high of $398.40.
Seelos Therapeutics (NASDAQ:SEEL – Get Free Report) last issued its earnings results on Tuesday, May 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The business had revenue of $0.58 million for the quarter.
Institutional Trading of Seelos Therapeutics
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
Featured Stories
- Five stocks we like better than Seelos Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Learn Technical Analysis Skills to Master the Stock Market
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.